384 related articles for article (PubMed ID: 28950235)
1. A physicochemical descriptor based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease.
Kumar A; Srivastava G; Sharma A
Comput Biol Chem; 2017 Dec; 71():1-9. PubMed ID: 28950235
[TBL] [Abstract][Full Text] [Related]
2. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease.
Kumar A; Srivastava G; Srivastava S; Verma S; Negi AS; Sharma A
J Mol Model; 2017 Aug; 23(8):239. PubMed ID: 28741112
[TBL] [Abstract][Full Text] [Related]
3. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
4. Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review.
Rampa A; Gobbi S; Concetta Di Martino RM; Belluti F; Bisi A
Curr Top Med Chem; 2017; 17(31):3361-3369. PubMed ID: 29332582
[TBL] [Abstract][Full Text] [Related]
5. Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments.
Bottegoni G; Veronesi M; Bisignano P; Kacker P; Favia AD; Cavalli A
ChemMedChem; 2016 Jun; 11(12):1259-63. PubMed ID: 26663255
[TBL] [Abstract][Full Text] [Related]
6. Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors.
Di Martino RM; De Simone A; Andrisano V; Bisignano P; Bisi A; Gobbi S; Rampa A; Fato R; Bergamini C; Perez DI; Martinez A; Bottegoni G; Cavalli A; Belluti F
J Med Chem; 2016 Jan; 59(2):531-44. PubMed ID: 26696252
[TBL] [Abstract][Full Text] [Related]
7. Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors.
Prati F; De Simone A; Bisignano P; Armirotti A; Summa M; Pizzirani D; Scarpelli R; Perez DI; Andrisano V; Perez-Castillo A; Monti B; Massenzio F; Polito L; Racchi M; Favia AD; Bottegoni G; Martinez A; Bolognesi ML; Cavalli A
Angew Chem Int Ed Engl; 2015 Jan; 54(5):1578-82. PubMed ID: 25504761
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease.
Prati F; De Simone A; Armirotti A; Summa M; Pizzirani D; Scarpelli R; Bertozzi SM; Perez DI; Andrisano V; Perez-Castillo A; Monti B; Massenzio F; Polito L; Racchi M; Sabatino P; Bottegoni G; Martinez A; Cavalli A; Bolognesi ML
ACS Chem Neurosci; 2015 Oct; 6(10):1665-82. PubMed ID: 26171616
[TBL] [Abstract][Full Text] [Related]
9. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
John S; Thangapandian S; Sakkiah S; Lee KW
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
[TBL] [Abstract][Full Text] [Related]
10. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
El Kerdawy AM; Osman AA; Zaater MA
J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
[TBL] [Abstract][Full Text] [Related]
11. Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease.
Prati F; Cavalli A; Bolognesi ML
Molecules; 2016 Apr; 21(4):466. PubMed ID: 27070562
[TBL] [Abstract][Full Text] [Related]
12. Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy.
Zagórska A; Jaromin A
Molecules; 2020 Jul; 25(15):. PubMed ID: 32717806
[TBL] [Abstract][Full Text] [Related]
13. The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor.
Razzaghi-Asl N; Karimi A; Ebadi A
Comput Biol Chem; 2018 Dec; 77():307-317. PubMed ID: 30445338
[TBL] [Abstract][Full Text] [Related]
14. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM
Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802
[TBL] [Abstract][Full Text] [Related]
15. BACE inhibitors as potential therapeutics for Alzheimer's disease.
Evin G; Kenche VB
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):188-99. PubMed ID: 18221231
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
17. Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease.
Ribaudo G; Coghi P; Zanforlin E; Law BYK; Wu YYJ; Han Y; Qiu AC; Qu YQ; Zagotto G; Wong VKW
Bioorg Chem; 2019 Jun; 87():474-483. PubMed ID: 30927588
[TBL] [Abstract][Full Text] [Related]
18. Progress toward a practical BACE-1 inhibitor.
Hills ID; Vacca JP
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):383-91. PubMed ID: 17659479
[TBL] [Abstract][Full Text] [Related]
19. Progress toward the discovery and development of efficacious BACE inhibitors.
Durham TB; Shepherd TA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
[TBL] [Abstract][Full Text] [Related]
20. Biological evaluation and energetic analyses of novel GSK-3β inhibitors.
Zhang D; Liu L; Pang L; Jin Q; Ke K; Hu M; Yang J; Ma W; Xie H; Chen X
J Cell Biochem; 2018 Apr; 119(4):3510-3518. PubMed ID: 29144001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
